This article is more than 5 years old. Information may no longer be current.
Advanced diagnostic test for Sjögren’s syndrome launched
Click Here to Manage Email Alerts
Nicox today announced the US launch of an advanced diagnostic test for the earlier detection of Sjögren’s syndrome.
Sjö, a proprietary laboratory test developed by Immco Diagnostics, combines traditional markers with three novel biomarkers that allows for earlier diagnosis of Sjögren’s syndrome, according to a press release. Under an agreement signed with Immco, Nicox is promoting the product in select markets to eye care professionals, who are in a position to identify dry eye as a significant and early symptom of the condition. The agreement also includes marketing rights in Canada, Puerto Rico and Mexico.
Patients with Sjögren’s syndrome have immune cells that target moisture-producing glands, resulting in dry eye. Many Sjögren’s syndrome patients first see an eye care practitioner with symptoms mistaken for routine dry eye.
“We [also] are pleased to partner with the Sjögren’s Syndrome Foundation to increase awareness of this serious and underdiagnosed condition among eye care practitioners across the country,” Jerry St. Peter, executive vice president and general manager of Nicox, said in the release.
“This partnership will help educate eye care professionals about the seriousness of Sjögren’s and encourage them to identify potential Sjögren’s patients, enabling them to receive proper diagnosis and timely medical care to treat this serious autoimmune disease,” Steven Taylor, chief executive officer at the Sjögren’s Syndrome Foundation, said in the release.
Patients have an average delay of 4.7 years to receive an accurate diagnosis of Sjögren’s syndrome, often identified after gland degradation has occurred, according to the release.
Primary responsibility for diagnosing and managing Sjögren’s syndrome is held by rheumatologists, the release stated. Symptoms often mimic other diseases, including lupus, rheumatoid arthritis and fibromyalgia.